# US 2025/0144181 A1 · Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144181 A1
- Document ID: US20250144181A1
- Status: Published application
- Kind: A1
- Application number: 19/016,974
- Filed: 2025-01-10
- Published: 2025-05-08
- Earliest claimed: 2018-11-19
- Assignees: 4Moving Biotech; Sorbonne Universite
- Applicants: 4Moving Biotech; Sorbonne Universite
- Inventors: Francis BERENBAUM; Revital RATTENBACH
- Web page: https://patentgrep.com/patent/US20250144181A1

## CPC

- A61K 38/26: Glucagons
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/38: Albumins
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and/or stem cell differentiation into chondrocytes.

## Claims

### Claim 1

A method for improving synovial membrane health in an osteoarthritis patient, comprising administering to said patient Glucagon Like Peptide-1 (GLP-1) or a GLP-1 analogue, or a composition comprising said GLP-1 or GLP-1 analogue.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method is for reducing synovitis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the method is for reducing synovial fibrosis, and wherein the GLP-1 or GLP-1 analogue or the composition is administered intra-articularly.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the GLP-1 analogue is selected from the group consisting of exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, and semaglutide.

### Claim 5 (depends on 1)

The method according to claim 1, wherein GLP-1 analogue is liraglutide.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the concentration of said GLP-1 analogue is of about 0.1 nM to 625 μM.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition comprises at least 5% of more weight of a pharmaceutically acceptable formulation vehicle to be used in combination.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the pharmaceutically acceptable formulation vehicle is albumin.
